INDIA
Country's top drug regulator is evaluating the application submitted by four domestic pharma giants.
India is soon going to have its domestic production of anti-viral Remdesivir drug, which would have safety, efficacy and stability for "restricted emergency use" on COVID-19 patients.
Recently, in the wake of the COVID-19 pandemic, the Drug Controller General of India (DCGI) has given the approval to Remdesivir for "restricted emergency use" on severely ill hospitalised coronavirus patients.
For this, the country's top drug regulator is evaluating the application submitted by four domestic pharma giants who want to seek the approval to manufacture and sell Remdesivir in India.
"Their applications are being thoroughly studied and examined day and night. It had certain shortcomings for which the respective pharma companies are furnishing their report. The testing of the drug's molecular compound will be done at our government laboratory. When it fulfils the safety parameters at the dose, India would soon have the benefit of its domestic product (Remdesivir) which have efficacy, stability and safety for 'restricted emergency use' on COVID-19 patients," a senior government official told ANI.
"Remdesivir is a drug that is still under trial. Hence, looking at the COVID-19 situation in the country, it has been permitted for 'restricted emergency use' on COVID-19 patients. Doctors have to get the consent-form duly filled by the patient in a prescribed manner before using it," he stated, adding that it is the first drug in India which has such strong control.
"The drug will be administered in the form of an injection in five doses. On the first day, a patient will be given two doses followed by one dose for the next four days under the strict monitoring of doctors. The drug has to be given only to those severe COVID-19 patients with oxygen saturation level below 94 and respiratory rate more than 24," the senior government official further said.
He informed that in other countries, patients are being administrated with 10 doses of Remdesivir.
Besides this, companies have to follow up each and every patient's case with regard to the safety and efficacy of the drug to whom it is being administered.
"Pharma companies have been directed to conduct Active-Post Marketing Surveillance of each case and prepare a report on the benefit or recovery of a patient and provide the data report to us," the official said, adding that these pharma companies have to submit a report to the government and also of a clinical trial being conducted anywhere in the world.
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19. However, multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of the drug as a treatment for the virus.
In the recent past, Gilead had signed non-exclusive voluntary licensing agreements with four generic pharma firms -- Cipla, Jubilant Life Sciences, Hetero and Mylan to manufacture and distribute Remdesivir, a potential antiviral therapy for COVID-19.
According to Gilead, under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for Remdesivir to enable them to scale up production more quickly.
UPSC introduces changes in online application process after aspirants' complaints; check here
TRAI's BIG move, introduces new rules against pesky calls, messages, fines telcos for...
Vir Das breaks his silence on India’s Got Latent controversy: 'A good artist will always…'
Who was Kim Rieul? Korean designer behind BTS and MONSTA X’s modern hanboks passes away at 32
Trade Compliance Meets Cybersecurity: Forensic Strategies for Risk Management
Enabling governance to organizations within AWS marketplace: A look at private marketplace
R Madhavan makes BIG STATEMENT about his bank account: 'I don't know how much I have and...'
Asense Interior: Celebrating 11 Years of Redefining Luxury Interiors in Bengaluru
Snow Moon 2025: When and how to witness February's full moon tonight? Know here
Kiss Day 2025: Why do we celebrate this day? Know history and significance
DNA Verified: Is Rashtrapati Bhavan hosting a wedding for the FIRST time? Know truth here
India's retail inflation slows to 4.31 per cent in January due to...
WATCH: Maha Kumbh girl Mona Lisa starts training before filming her 1st movie alongside Anupam Kher
Radhika Merchant stuns in blue and green suit at MahaKumbh Mela, it costs Rs....
BIG move by Mukesh Ambani, Reliance partners with US company, set to drive...
IND v ENG: Why are India and England players wearing green arm bands in 3rd ODI at Ahmedabad?
Tripti Dimri sets major beachwear goals in Maldives; can you guess price of her swimsuit?
Mitolyn Supplement Reviews: Ingredients, benefits, side effects, purple peel exploit
Gaurav Sharma: Visionary leader driving cybersecurity excellence
All About Details: Turning ordinary outfits into statement looks
Duolingo owl is dead? Launguage learning app urges users to respect Dua Lipa's privacy, know why
Why digitisation is necessary in construction industry and why its adoption remains slow
Meet IIT-JEE topper, who created record in Odisha by scoring 99.98 percentile, aims to join...
When is Shab-e-Barat 2025 – February 13 or 14? Check history, significance
THIS is India's last railway station where train never stops, know why
GBS outbreak: Mumbai reports its first death due to Guillain-Barre Syndrome
Ram Gopal Varma questions Rajinikanth's acting, says 'I don’t know if he can exist without...'
Who was Acharya Satyendra Das? Ayodhya Ram temple's chief priest who passed away in Lucknow
Old wedding card mentioning IIT degrees of couple creates buzz on social media; see viral post
Chunky Panday says Shatrughan Sinha advised him to 'make people wait': 'If you are punctual...'
UP Court summons Rahul Gandhi on March 24 over 2022 remarks against Army
Indian consulate in Marseille to strengthen 'people-to-people ties': PM Modi
India’s Top 5 Richest YouTubers: Know who’s earning more than Samay Raina and Ranveer Allahbadia?
Mukesh Ambani, Sunil Mittal are working to revolutionise mobile calling in India by...
DNA TV Show: UP CM Yogi Adityanath's multi-level plan for Maghi Purnima
Tejasswi Prakash reveals why she joined Celebrity MasterChef: 'I am obsessed with...'
Delhi-NCR schools holiday: Delhi, Noida, Gurugram, Ghaziabad, schools closed tomorrow due to...
'We can teach children AI but...': Sudha Murty urges govt to provide funds to schools to promote...
THIS startup gives whopping bonus to employees for loyalty, they get Rs...
JEE Main 2025 Toppers List Released: Meet 14 candidates who scored 100 percentile this year
JEE Main Result 2025 DECLARED: Get direct link, steps to check NTA score and other details HERE
SHOCKING! Noida family held under ‘digital arrest’ for 5 days, loses Rs 1 crore to cyber fraud
Ranveer Singh, Akshaye Khanna shoot for Aditya Dhar's Dhurandhar in Mumbai, pictures get leaked
Why are hobby classes integral to Podar International School’s curriculum in Khopoli?
Mukesh Ambani buys Rs 6437604000 stake in THIS cricket team, not Mumbai Indians